Introduction {#Sec1}
============

Colorectal cancer is the third most common cancer and the fourth most prevalent cause of death in the world \[[@CR46]\]. Approximately 35--45% of patients with colorectal tumors have mutation in *KRAS* gene, while *BRAF* V600E mutation is found in about 5--15% of colorectal adenocarcinomas \[[@CR8], [@CR9], [@CR26], [@CR31]\]. Both these mutations are considered to be oncogenic driver mutations, since they are both responsible for the initiation and maintenance of the tumor \[[@CR10]\]. Importantly, many studies have indicated that *BRAF* V600E mutation occurs only in tumors that do not carry mutations in *KRAS* gene and it is widely accepted that these two mutations are mutually exclusive \[[@CR10], [@CR23], [@CR25], [@CR30]\].

The *BRAF* gene encodes a cytoplasmic serine-threonine kinase that is frequently mutated in various cancers, including melanoma, papillary thyroid carcinoma, and colorectal carcinoma, among others. The oncogenic mutations in *BRAF* gene result in constitutive activation of the MAPK signaling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of these mutations, the V600E mutation, occurs in exon 15 and results in a substitution from valine to glutamic acid at position 600 within the BRAF kinase domain.

*BRAF* V600E mutation occurs in about 5% of microsatellite stable (MSS) CRC tumors. These tumors are associated with a distinct molecular and clinical phenotype with a poor prognosis \[[@CR40]\]. The presence of *BRAF* V600E mutation in CRC is associated with poor survival \[[@CR44]\]. *BRAF* V600E mutation is also detected in sporadic CRC tumors with microsatellite instability (MSI) \[[@CR27]\]. Particularly, *BRAF* V600E mutation is observed in about two thirds of MSI tumors with the loss of MLH1 expression due to MLH1 promoter methylation \[[@CR18]\]. In contrast, *BRAF* V600E mutation is very rare in CRC patients with Lynch syndrome \[[@CR27]\]. In clinical practice it is much easier to detect *BRAF* V600E mutation than methylation status of MLH1 promoter \[[@CR26]\]. Therefore, it was suggested that assessment of *BRAF* V600E mutation can be used to triage patients for mismatch repair (MMR) genetic testing to differentiate MLH1-deficient sporadic CRC from Lynch syndrome caused by germ-line *MLH1* mutations \[[@CR7], [@CR14], [@CR17], [@CR26], [@CR41], [@CR43]\]. Currently, the American National Comprehensive Cancer Network (NCCN) guidelines recommend that *BRAF* V600E mutational status should be evaluated in all colorectal carcinomas to identify 1) the patients with Lynch syndrome in MMR deficient group and 2) to identify the MMR proficient/BRAF V600E group with poor prognosis \[[@CR15], [@CR38], [@CR43]\].

The most common approach for the detection of *BRAF* mutation is sequencing of tumor DNA, for example Sanger sequencing, pyrosequencing and high resolution melting. All of these methods are able to detect a mutant allele in a background of 5--20 fold excess of wild-type alleles. In contrast, immunohistochemistry allows direct visualization of the mutant protein in the tumor cells in tissue context. The anti-BRAF V600E (VE1) antibody is currently used to evaluate the *BRAF* V600E mutation status in various cancers including CRC \[[@CR32]\]. This antibody is a mutation-specific mouse monoclonal antibody that was raised against a synthetic peptide representing the *BRAF* V600E mutated amino acid sequence from amino acids 596 to 606 (GLATEKSRWSG) \[[@CR5], [@CR6]\].

The primary goal of this study was to compare the performance of the anti-BRAF V600E (VE1) antibody to detect *BRAF* V600E mutation by IHC in colon cancer cases with/without *KRAS* mutation. Since concomitant *KRAS* and *BRAF* tumor mutations are considered mutually exclusive we wanted to confirm that the CRC cases carrying *KRAS* mutation show negative BRAF V600E staining by IHC with anti-BRAF V600E (VE1) antibody. In addition, we performed a review of 25 studies that compared IHC using anti-BRAF V600E (VE1) antibody with molecular testing for *BRAF* V600E mutation.

Materials and Methods {#Sec2}
=====================

Tumor Specimens {#Sec3}
---------------

A total of 120 formalin-fixed paraffin embedded (FFPE) tissues from patients with colorectal cancer were ordered from Avaden Biosciences and GLAS/Consultants in Human Biologics. The requested cases included 60 CRC cases with confirmed *KRAS* mutation, 30 CRC cases with confirmed *BRAF* V600E mutation and 30 CRC cases confirmed to be wild-type BRAF and wild-type KRAS. The presence/absence of these mutations was confirmed by molecular testing by the vendor.

BRAF V600E Immunohistochemistry {#Sec4}
-------------------------------

Four 4 μm thick sections were cut from the FFPE blocks. The testing was performed using anti-BRAF V600E (VE1) mouse monoclonal primary antibody (Ventana Medical Systems, Inc., Cat. Number 790--4855) the BenchMark ULTRA platform with Cell Conditioning 1 for 64 min, pre-peroxidase inhibition and primary antibody incubation for 16 min at 37 °C. Final concentration of the antibody was \~12 μg/ml. The OptiView DAB IHC Detection Kit (Ventana Medical Systems, Inc.) was used to detect *BRAF* V600E protein expression. Tissues were counterstained with Hematoxylin II (Ventana Medical Systems, Inc.) and Bluing Reagent (Ventana Medical Systems, Inc.) for 4 min. To measure the level of non-specific background signal, each tissue was also stained with a mouse monoclonal antibody (MOPC-21) \[Negative Control (Monoclonal), Ventana Medical Systems, Inc.\]. This antibody is not directed against any known epitope present in human tissue. In addition, slides containing 2 cases positive for *BRAF* V600E mutation (CRC, thyroid papillary carcinoma) and one case negative for *BRAF* V600E mutation (CRC) were used as run control slides. The absence/presence of the *BRAF* V600E mutation in the tissues was confirmed by Sanger sequencing. These slides were included with each individual run to assess the expected quality of the antibody and all components of the assay. The overall run was accepted if: 1) the *BRAF* V600E positive tissue control stained with anti-BRAF V600E (VE1) antibody showed specific cytoplasmic staining pattern and had acceptable background; 2) the positive tissue control stained with Negative Control Monoclonal shows no specific staining and had acceptable background; 3) the BRAF V600E negative tissue control stained with anti-BRAF V600E (VE1) antibody showed no specific staining pattern and acceptable background; and 4) the BRAF V600E negative tissue control stained with Negative Control (Monoclonal) shows no specific staining and has acceptable background.

The stain intensity of anti-BRAF V600E (VE1) antibody in tumor cells was recorded on a 0--3 scale. Strong cytoplasmic staining was scored as 3, medium cytoplasmic staining as 2, weak cytoplasmic staining as 1 and the absence of staining was scored as 0. In addition, any nuclear staining and the percentage of tumor cells stained positive with anti-BRAF V600E (VE1) antibody was recorded. The criteria for positive BRAF V600E staining included unequivocal, diffuse, uniform, cytoplasmic staining at intensity ≥1 in majority of malignant cells. The cases were scored as negative for BRAF V600E mutation if they showed no staining or weak, cytoplasmic, non-granular, uniform staining (stain intensity \<1). The cases with staining of isolated tumor cells in a tumor that otherwise showed no staining were also scored as negative. The cases were scored as equivocal if they displayed ambiguous, heterogeneous, non-uniform cytoplasmic staining in tumor cells with or without nuclear staining. The equivocal cases were sequenced by Sanger sequencing to confirm the presence/absence of *BRAF* V600E mutation.

BRAF V600E Sanger Sequencing {#Sec5}
----------------------------

Genomic DNA was extracted from 20 μm thick sections from FFPE samples using the QIAamp FFPE Tissue Kit (Qiagen, Redwood, CA) according to manufacturer's instructions. The primers for Sanger sequencing were designed to amplify region of the exon 15 of the *BRAF* gene coding sequences at mutation site and a few nucleotides in the intron on both ends. Two primers were used including 1) BRAF-ex15F-TGCTTGCTCTGATAGGAAAATG and 2) BRAF-ex15R-AGCATCTCAGGGCCAAAAAT. Both forward and reverse strands were sequenced on an Applied Biosystem's 3730xl DNA Analyzer and analyzed using DNASTAR Lasergene 12 software (DNASTAR, Madison, WI).

Results {#Sec6}
=======

Anti-BRAF V600E (VE1) Immunohistochemistry {#Sec7}
------------------------------------------

All 120 cases were examined for presence of *BRAF* V600E mutation by IHC using the anti-BRAF V600E (VE1) antibody on the automated VENTANA BenchMark ULTRA platform.

All 30 cases with *BRAF* V600E mutation exhibited uniform, unequivocal, diffuse, cytoplasmic staining in majority of tumor cells with stain intensities of 1--2.75 and background ≤0.25. Out of 30 cases, 28 cases showed positive BRAF V600E signal in 100% of tumor cells and 2 cases showed positive staining in 90% and 85% of tumor cells, respectively. These data are consistent with previous reports indicating that majority of tumor cells express mutated *BRAF* V600E protein, since this mutation is driving tumor proliferation. All 30 cases with no *BRAF* V600E and no *KRAS* mutations showed intensities of ≤0.5 and background ≤0.25. In 28 cases the stain intensities were 0--0.25, in remaining two cases 10% and 85% of malignant cells stained at the stain intensities 0.5. The sensitivity and specificity was 100% for cases with confirmed *BRAF* V600E mutational status. Representative images are shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Representative images of eight colon cancer cases stained with anti-BRAF V600E (VE1) mouse monoclonal antibody. BRAF V600E mutation was confirmed in cases shown in images A,B,E,F,I,J,M,N by molecular testing, no BRAF V600E mutation was detected by molecular testing in cases shown in images C,D,G,H,K,L,O,P. Magnification 10× (A,C,D,E,G,I,K,M,O) and 20× (B,D,F,H,J,L,N,P)

Out of 60 CRC cases with *KRAS* mutations 56 cases were scored as negative for *BRAF* V600E mutation (stain intensity \<1). There were four cases where the stain intensities were scored as 1. However, these four cases exhibited ambiguous, heterogeneous, non-uniform cytoplasmic staining along with nuclear staining and thus they were scored as equivocal. In the first case, only 40--50% of tumor cells were positively stained with anti-BRAF V600E (VE1) antibody, the cells with positive staining showed the signal in cytoplasm and also strong signal in nuclei, the cytoplasmic staining was non-diffuse and non-uniform. Representative images are shown in Fig. [2A-C](#Fig2){ref-type="fig"}. In the second case only small portion of tumor showed uneven, cytoplasmic staining (25% tumor cells). In addition, tumor cells also exhibited nuclear staining. Representative images are shown in Fig. [2D-F](#Fig2){ref-type="fig"}. Third case showed staining in 70% of cells, however the staining was heterogeneous and clearly nuclear along with lighter non-uniform cytoplasmic staining. Representative images are shown in Fig. [2](#Fig2){ref-type="fig"} G-I. Fourth case showed high degree of nuclear staining, overall 90% of tumor cells showed positive staining in cytoplasm, however the strong staining was observed in nuclei with some signal in cytoplasm. This cytoplasmic staining was scattered and uneven. Representative images are shown in Fig. [2J-L](#Fig2){ref-type="fig"}. Since these four case exhibited ambiguous, non-uniform, heterogeneous and nuclear staining pattern, they were assigned as equivocal for *BRAF* V600E mutation.Fig. 2Representative images of four colon cancer cases with KRAS mutation showing equivocal staining. The tissues were stained with anti-BRAF V600E (VE1) mouse monoclonal antibody (A,B,D,E,G,H,J,K) and negative reagent control (C,F,I,L) \[A,B,C - case 1; D,E,F - case 2; G,H,I - case 3; J,K,L - case 4, Magnification - 10× (A,D,G,J), 20× (B,C,E,F,H,I,K,L)\]

In addition, there were 4 cases that were scored with stain intensity of 0.75 in all three evaluated slides in 30--90% of tumor cells. All these cases exhibited nuclear staining and non-diffuse, weak, heterogeneous cytoplasmic staining. Since the stain intensity was \<1 these cases were scored as negative for *BRAF* V600E mutation.

DNA Sequencing {#Sec8}
--------------

Overall, out of the all 120 cases, there were 60 cases with *KRAS* mutation. Out of these 60 cases, 4 cases showed BRAF V600E stain intensity 1 in 25--90% of tumor cells. This was not expected since these *KRAS* and *BRAF* V600E are mutually exclusive mutations. These cases exhibited the staining pattern that was not consistent with the recommendations based from studies shown in Table [1](#Tab1){ref-type="table"} that include uniform, diffuse, cytoplasmic staining in majority of malignant cells. In addition, 4 *KRAS* mutated cases showed stain intensities 0.75 with similar nuclear/heterogeneous staining pattern. These cases were also sequenced for *BRAF* V600E mutation. All these cases were negative for *BRAF* V600E mutation by Sanger sequencing.Table 1Scoring criteria used for BRAF V600E expression in CRC by IHC\#AuthorCRC TissuesBRAF V600E Scoring CriteriaNotes from the publications on BRAF V600E scoring/staining1Adackapara et al. \[[@CR1]\]52 casesScoring criteria: negative, weak, moderate, strong, (any cytoplasmic staining even a blush scored as weak)Moderate to strong cytoplasmic staining; relatively uniform staining throughout all positive cases, non-specific nuclear staining common.2Affolter et al. \[[@CR2]\].31 casesScoring criteria: based on the intensity of cytoplasmic staining, percentage of tumor cells stainedStaining in the majority of BRAF mutant cases was strong and diffuse. Semiquantitative analysis of stain intensity or percentage of staining cells was not useful, because most tumor cells stained in positive cases and staining was uniformly absent in negative cases. No indeterminate cases. Heterogeneous or weak staining occurred infrequently. Cilia, nuclei of colonocytes sometimes positive.3Bledsoe et al. \[[@CR3]\]204 casesPositive case: cytoplasmic staining, uniform to near uniform, intensity -weak to strong.Pitfalls include signet-ring cell morphology. Dim but uniform staining should not be disregarded. Nuclear staining in normal cells. Nuclear staining occurred only in a minority of BRAF mutants, was regarded as nonspecific, and, in the absence of the cytoplasmic criteria, was taken as non-diagnostic. Nonspecific nuclear and heterogeneous, non-diffuse cytoplasmic staining of variable intensity was observed in occasional non--BRAF-mutant cases.Scoring criteria: negative, weak, moderate, strong. Diffuse or non-diffuse. Uniform (all malignant cells) or near uniform, heterogeneous (variable stain intensity).4Capper et al. \[[@CR7]\]91 casesPositive case: staining of \>80% tumor cells above backgroundHomogenous finely granular cytoplasmic staining was seen in most cases. No single anti-BRAF V600E (VE1) antibody positive cells or positive clonal foci in otherwise negative tumors were observed.5Day et al. \[[@CR9]\]477 casesPositive case: unequivocal cytoplasmic staining above background in the majority of invasive viable tumor cells.Any nuclear staining, weak, cytoplasmic staining of isolated tumor cells or focal confluent staining of tumor cells in a tumor that otherwise showed no staining was scored as immune-negative.6Dvorak et al. \[[@CR11]\] \*279 casesPositive case: diffuse cytoplasmic staining of \>80% tumor cellsHeterogeneous staining in 3 cases out of 238 CRC on TMA7Kuan et al. \[[@CR19]\]128 casesScoring criteria: 3+, 2+, 1+, 0Scoring assessment based on stain intensity is appropriate. Weak even diffuse staining (1+) is not diagnostic and requires testing by PCR analysis.8Lasota et al. \[[@CR20]\]113 casesScoring criteria: negative, weak, moderately positive, strongly positive2 KRAS cases false positive, suboptimal protocol used9Loes et al. \[[@CR21]\]99 casesScoring criteria: 0-no staining, 1-weak diffuse cytoplasmic staining, 2 moderate diffuse, granular cytoplasmic staining, 3- strong diffuse granular cytoplasmic staining; 0--1 negative, 2--3 positiveIn positive samples the staining was homogeneous with equal intensity throughout the majority of tumor cells.10Rossle et al. \[[@CR33]\]68 casesScoring criteria: 0- negative, 1 weakly/moderately positive, 2 strongly positive.Diffuse staining of variable intensity (from weak to strong) in most cases. False positive staining noted in signet ring tumor cells.Positive case: unequivocal cytoplasmic staining of a majority of tumor cells,11Roth et al. \[[@CR34]\]55 casesPositive case: Uniform diffuse cytoplasmic staining (even week) in all tumor cellsMost cases --strong, diffuse, uniform cytoplasmic staining, a few cases showed weaker but diffuse and convincingly cytoplasmic staining12Sinicrope et al. \[[@CR39]\]74 casesScoring criteria: 0 none, 1+ weak, 2+ medium, 3+ strong)Homogenous staining seen in the majority of cases. Any nuclear staining or weak interspersed staining was scored as negative. Any nuclear staining or weak staining of interspersed cells was scored as negative. BRAF V600E expression was homogeneous. 100% of tumor cells stained in 75% cases, \>70% cells stained in all cases.Positive case: at least 70% tumor cells stained13Toon et al. \[[@CR43]\]201 casesPositive case: diffuse strong positive staining of \>75% of malignant cellsThe great majority of positive cases actually demonstrated diffuse strong homogenous cytoplasmic staining in essentially all malignant cells, whereas the great majority of negative cases showed completely absent staining in all malignant cells. Patchy non-specific staining in smooth muscle cells, mucin, and colonic mucosa (with nuclear staining). Weak but diffuse staining seen occasionally in positive cases.14Piton et al. \[[@CR28]\]30 casesPositive case: \>10% tumor cells showed positive signal..BRAF mutants -- staining homogeneous, cytoplasmic, finely granular. Any nuclear staining was ignored and not scored.15Qui et al. \[[@CR29]\]\*181 casesCytoplasmic stainingThe interpretation of the results was clear. The negative and positive samples can be easily distinguished without the need of a subjective IHC scoring system based on stain intensity or percentage of positively stained cells.16Thiel et al. \[[@CR42]\]176 casesPositive case: detectable granular cytoplasmic stainingNo details17Hang et al. \[[@CR13]\]425 casesScoring criteria: negative (0), weak (1+), moderate (2+), strong (3+)2 cases heterogeneous staining, 70% cells stained, 8/425 cases were called equivocal due to low stain intensity18Schafroth et al. \[[@CR37]\]33 casesScoring criteria: cytoplasmic staining -- weak to strongInterpretation of weak staining is challenging. About 10% of cases -- weak staining, these cases should be validated by another method. Nuclear staining sometimes observed in tumor cells- considered negative. Heterogeneity -- minimal.19Estrella et al. \[[@CR12]\]480 casesScoring criteria: 0-negative, 1- weak in \<20% tumor cells, 2-moderate to strong in \<20% tumor cells, 3 weak in 20--70% tumor cells, 4-moderate or strong in 20--70% tumor cells, 5 weak in \>70% tumor cells, 6 moderate to strong in \>70% tumor cells.Scoring system was completely different than other studies.Positive case: also cases with 20--70% cells stained \[[@CR8]--[@CR10], [@CR31]\]20Vakiani et al. \[[@CR45]\]117 casesScoring criteria: Weak, moderate, strong.In majority of the cases, positive/negative score- readily achieved. Equivocal - 4 cases, 3 cases- nuclear staining in tumor cells, 1 case focal nuclear and weak cytoplasmic, mucinous carcinoma, or signet ring.Positive case: \>80% cell tumor staining above any background staining,Equivocal case: nuclear staining with cytoplasmic staining in tumor cells.21Boulagnon et al. \[[@CR4]\]86 casesPositive cases: (cytoplasmic, diffuse, moderate to intense), Negative cases: no or faint cytoplasmic stainingOnly 3 cases equivocal because of heterogeneous staining patternEquivocal case: heterogeneous, or weak staining22Sajanti et al. \[[@CR36]\]147 casesPositive case: diffuse staining in the tumor cellsAll BRAF mutated CRCs showed diffuse and strong staining23Routhier et al. \[[@CR35]\]25 casesPositive case: diffuse and moderate to strong cytoplasmic staining of tumor cell.No details.Negative case: isolated nuclear staining, weak staining of occasional cells or faint diffuse staining --24Nolan et al. \[[@CR24]\]152 casesPositive case: diffuse cytoplasmic staining of \>80% tumor cells, ranging from medium to strong in strength.This study included also equivocal category -- PCR confirmatory test needed for these cases. Only 8 equivocal cases.Negative case: absent staining or very weak staining of similar intensity to the control normal mucosa,Equivocal case: heterogeneous staining25Ilie et al. \[[@CR16]\]489 casesPositive case: \>80% cell tumor staining, strong, distinct, homogeneous stainingEquivocal cases --additional analysis required for such casesEquivocal case: ambiguous, focal, moderate staining

Disscussion {#Sec9}
===========

This study evaluated 120 CRC cases with and without *KRAS* mutation to access the performance of IHC using anti-BRAF V600E (VE1) antibody for detection of *BRAF* V600E mutation. Overall, the results of these experiments demonstrates that IHC using the anti-BRAF V600E (VE1) antibody with the VENTANA OptiView DAB detection system and BenchMark ULTRA platform is a highly specific and sensitive method for the detection of *BRAF* V600E in colon cancer.

There is strong evidence from multiple studies that the IHC using anti-BRAF V600E (VE1) antibody is highly concordant with molecular tests for the *BRAF* V600E mutation. Table [2](#Tab2){ref-type="table"} shows a summary of 25 studies that evaluated sensitivity and specificity of IHC with anti-BRAF V600E (VE1) antibody in comparison with molecular tests using different methods (Sanger, pyroseqencing, SNapShot PCR, NGS, etc.). Altogether, 4041 patient samples were evaluated in these studies, the overall sensitivity and specificity of IHC assay using anti-BRAF V600E (VE1) antibody compared to molecular tests was 93% (934/1008) and 96% (2922/3033), respectively.Table 2Summary of immunohistochemical studies using anti-BRAF V600E (VE1) antibody compared to molecular testingFirst authorMolecular testingTissue sourceInstrument/ Detection*Sensitivity %*(n/N)Specificity %(n/N)Antibody/dilutionAntigen retrieval /antibody incubation1Adackapara et al. \[[@CR1]\]PyrosequencingWSManual/ Not specified71% (12/17)74% (26/35)Spring 1:50Citrate buffer pH 6/overnight 4 °C2Affolter et al. \[[@CR2]\].PyrosequencingWSBMK ULTRA/ ultraView Amplification100% (14/14)100% (17/17)Spring 1:600Manual AR/60 min antibody3Bledsoe et al. \[[@CR3]\]Multiplex PCR, SNaPshotTMA, WSLeica/Bond-III96% (57/59)99% (143/145)Spring 1:10040 min EDTA buffer pH 9 / Not specified4Capper et al. \[[@CR7]\]Sanger and pyrosequencingWSBMK XT/ OptiView Amp100% (11/11)99% (79/80)Hybridoma 1:564 min CC1/32 min antibody5Day et al. \[[@CR9]\]Sanger and SNaPShotTMA, WSBMK XT/OptiView, ultraView100% (59/59)100% (416/416)Hybridoma 1:364 min CC1/16 min antibody6Dvorak et al. \[[@CR11]\] \* ++Sanger, SNapShot, and NGSTMA, WSBMK XT/ OptiView100% (86/86)99% (191/193)Ventana 1:5064 min CC1/16 min antibody7Kuan et al. \[[@CR19]\]PCRWSBMK ULTRA/OptiView100% (74/74)94% (51/54)Spring 1:20056 min CC1/20 min antibody8Lasota et al. \[[@CR20]\]\*\*Multiple analyses, CobasWSLeica/ Bond-Max/Polymer detection89% (24/27)78% (64/86)Spring 1:20025 min Bond Epitope retrieval solution 1/30 min antibody9Loes et al. \[[@CR21]\]\*Sanger and LightMixTMABMK XT/OptiView59%(13/22)84% (63/75)Spring 1:6064 min CC1/16 min antibody10Rossle et al. \[[@CR33]\]Sanger and ultra-deep sequencingWSBMK XT/OptiView100% (37/37)95% (20/21)Spring 1:20064 min CC1/32 min antibody11Roth et al. \[[@CR34]\]Multiplex PCRTMA, WSLeica Bond/ Not specified88% (28/32)100% (23/23)Spring 1:90020 min Leica Bond EDTA solution pH 9/15 min antibody12Sinicrope et al. \[[@CR39]\]Multiplex PCRWSBMK XT/OptiView100% (49/49)100% (25/25)Spring 1:45Not specified/16 min antibody13Toon et al. \[[@CR43]\]Multiplex PCR, MSWSNot specified97% (37/38)96% (157/163)Hybridoma/Not specifiedNot specified/ Not specified14Piton et al. \[[@CR28]\]SNapShotWSManual/DAKO EnVision100% (10/10)100% (20/20)Spring Not specified30 min citrate buffer pH 6/16 min antibody15Qui et al. \[[@CR29]\]\* ++Sanger, RT-PCR, CobasWSBMK not specified/OptiView100% (38/38)100% (143/143)Ventana 1:5064 min CC1/16 min antibody16Thiel et al. \[[@CR42]\]PCRTMABMK XT/OptiView or ultraView with/ without Amp100% (26/26)100% (129/129)Spring 1:2000Not specified/ Not specified17Hang et al. \[[@CR13]\]PCRTMALeica Bond-Max /Bond Polymer Refine detection91% (21/23)99% (397/402)Spring 1:20030 min Bond Epitope retrieval solution 2 /15 min antibody18Schafroth et al. \[[@CR37]\]PyrosequencingTMA, WTBMK ULTRA/ OptiView100% (18/18)93% (14/15)Ventana 1:5072 min CC1/40 min antibody19Estrella et al. \[[@CR12]\]Different methodsWTLeica Bond/Bond Polymer Refine detection75% (106/142)93% (315/338)Spring 1:5020 min TRIS-EDATA buffer pH 9/Not specifiedBMK ULTRA/ OptiView89% (51/57)57% (20/35)64 min CC1/ Not specified20Vakiani et al. \[[@CR45]\]PCR, SangerWTBMK XT/OptiView94% (45/48)96% (66/69)Spring 1:5032 min AR/32 min antibody21Boulagnon et al. \[[@CR4]\]RT-PCRTMA, WTBMK XT/ ultraView95% (20/21) TMA 100% (21/21) WT92% (60/65) TMA 95% (62/65) WTAbcys EuroBio 1:5064 min CC1/32 min antibody22Sajanti et al. \[[@CR36]\]PCRTMABMK XT/ OptiView Ampl100% (13/13)99% (133/134)Spring 1:2000Not specified/ Not specified23Routhier et al. \[[@CR35]\]SNapShotWTLeica Bond 3/Leica Polymer Refine detection100% (17/17)100% (15/15)Spring 1:10040 min EDTA solution (Leica) /Not specified24Nolan et al. \[[@CR24]\]PCRWTBMK ULTRA/ ultraView Ampl93% (14/15)100% (59/59)Spring Not specified32 min CC1/32 min antibody25Ilie et al. \[[@CR16]\]Sanger, pyrosequencingWTBMK XT/OptiView94.2% (32/34)100% (276/276)Spring 1:50Not specified/ Not specified\*only CRC cases included++ Ventana anti-BRAF V600E (VE1) antibody and recommended protocol used, BMK XT\*\*data in text and table do not matchNS not specified, AR antigen retrieval, WS whole sections, TMA tissue microarray, Ampl amplification

Out of these 25 studies, 4 publications reported lower sensitivity and/or specificity of anti-BRAF V600E antibody compared to sequencing \[[@CR1], [@CR12], [@CR20], [@CR21]\]. However, there were several problems with these studies. First, the study by Adackapara et al. analyzed 52 colorectal carcinomas with known *BRAF* mutation status determined by pyrosequencing and found that IHC had a low sensitivity (71%) and specificity (74%) for detecting *BRAF* V600E mutation compared to pyrosequencing (Table [2](#Tab2){ref-type="table"}). They concluded that IHC using anti-BRAF V600E (VE1) antibody is not a useful surrogate for detecting *BRAF* mutation in colorectal carcinoma. However, in their experiment, manual staining with citrate buffer as antigen retrieval was employed. In our experience and the experience of others the use of acid for antigen retrieval step results in suboptimal staining that is difficult to interpret \[[@CR19]\]. TRIS or EDTA buffers at pH = 8 proved to be retrieval agents that produced the most robust and homogenous cytoplasmic staining with anti-BRAF V600E (VE1) antibody. Similarly, Lasota et al. used in their studies Bond Epitope Retrieval Solution 1 (pH = 6) which is not an optimal solution for antigen retrieval for this assay \[[@CR20]\].

Another important factor that may contribute to the different outcome of the studies is the interpretation of the IHC results. As multiple studies have highlighted, a proper scoring system is necessary to reduce false-positive and false-negative cases. Since *BRAF* V600E mutation is a driver mutation, a majority of tumor cells should express this mutated protein. The scoring criteria shown in Table [1](#Tab1){ref-type="table"} were used in the individual studies presented in Table [2](#Tab2){ref-type="table"} that compare IHC using anti-BRAF V600E (VE1) antibody with molecular testing for *BRAF* V600 E mutation. Overall, 14 out of 25 studies scored cases positive for *BRAF* V600E mutation when uniform or nearly uniform, diffuse staining was present in tumor cells or when the majority (≥ 75%) of tumor cells exhibited unequivocal cytoplasmic staining (Table [2](#Tab2){ref-type="table"}). All studies that used these interpretation criteria (and appropriate protocol using antigen retrieval at alkaline pH) reached close to 100% sensitivity and specificity compared to sequencing. Additional 7 studies did not include scoring criteria in the method section, however they reported that homogeneous, diffuse staining pattern was observed in cases with confirmed *BRAF* V600E mutation. Three studies provided no details. In one study the cases were scored as positive for BRAF V600E staining when only ≥20% tumor cells showed positive signal in one study \[[@CR12]\]. The sensitivity and specificity reported in this study was only 89% and 57% (when IHC assay on BenchMark ULTRA platform was used) and 75% and 93% (when IHC assay on Leica Bond was used). Several studies suggested that additional analysis is required for minority of equivocal cases with ambiguous, focal, heterogeneous staining (Table [2](#Tab2){ref-type="table"}). False positive staining was noted in signet ring tumor cells \[[@CR33]\]. Importantly, the nuclear staining was described as the most common artifact (Table [2](#Tab2){ref-type="table"}) \[[@CR22]\]. For example, Bledsoe et al. noted that *BRAF*-mutant cases showed homogeneous, finely granular, cytoplasmic staining with varying intensities, however, non-specific nuclear and heterogeneous non-diffuse cytoplasmic staining of variable intensity was observed in a minority of non-*BRAF* mutant cases \[[@CR3]\]. Therefore, it was recommended by Marin et al. that "the interpretation should be made with caution in the presence of nuclear staining" \[[@CR22]\]. Our study also suggests that the cases showing the presence of heterogeneous cytoplasmic staining with or without nuclear staining should be carefully interpreted.

Overall, the evidence from the publications presented in Table [1](#Tab1){ref-type="table"} and from the current study suggests that the cases should be scored as positive for *BRAF* V600E mutation if they display unequivocal, diffuse, uniform, granular, cytoplasmic staining in the majority of tumor cells at stain intensity ≥1. They should be scored as negative for *BRAF* V600E mutation if they exhibit no staining or weak, cytoplasmic, non-granular, non-uniform staining (stain intensity \<1). The cases with staining of isolated tumor cells in a tumor that otherwise showed no staining should be considered negative. The cases should be considered as equivocal if they display ambiguous, heterogeneous, cytoplasmic staining with or without nuclear staining in tumor cells. If these interpretation criteria are followed the IHC with anti-BRAF V600E (VE1) antibody using recommended protocol with OptiView detection is optimal for detection of *BRAF* V600E mutation in CRC. In our study all 30 cases with *BRAF* V600E mutation showed unequivocal positive cytoplasmic staining in 85--100% tumor cells; all 30 cases with wild-type *KRAS* and *BRAF* were negative; 6.7% (4/60) cases with *KRAS* mutation showed heterogeneous, cytoplasmic/nuclear staining at stain intensity 1. However, the staining was heterogeneous and the presence of distinct nuclear staining was noted in these four cases along with cytoplasmic staining. Therefore, these cases were assigned as equivocal for *BRAF* V600E mutation. These cases were sequenced and confirmed to be negative for *BRAF* V600E mutation.

In summary, this study indicates that IHC with the anti-BRAF V600E (VE1) antibody performed on the Benchmark ULTRA automated stainer is a highly sensitive and specific detection method for determination of *BRAF* V600E mutation status in CRC. The results presented in this study are consistent with previous reports indicating that *KRAS* and *BRAF* V600E mutation are mutually exclusive. Based on our findings and consistent with other literature reports, the majority of *BRAF* V600E positive cases demonstrate a uniform or nearly uniform, diffuse staining pattern present in the majority of tumor cells. We propose that in the minority of cases with an equivocal staining pattern, additional molecular testing should be done to assess *BRAF* mutational status.
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